Eric H. Zanelli

Dr. Eric Zanelli co-founded Allievex Corp. and serves as its Head of Research. In his role, he focuses on preclinical development including immunology, neuroscience, pharmacology, toxicology, biomarkers and translational medicine. Prior to the founding of Allievex, Eric served as Senior Scientific Advisor at CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), where he focused on the development of lasmiditan for the acute treatment of migraine headaches. He has also served in senior scientific management roles at Peptimmune Inc., Praecis Pharmaceuticals, Inc. and Cardion AG. Additionally, Eric is the Scientific Founder of Déclion Holdings LLC, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He is the co-author of 45 peer-reviewed scientific articles and a co-inventor or sole inventor of 12 families of granted or pending patent applications.

Prior to his industry roles, Eric was a Senior Investigator at the Leiden University Medical Center, Leiden, The Netherlands, from 1996 to 2000 and a Postdoctoral Fellow in the Department of Immunology at the Mayo Clinic, Rochester MN, from 1992 to 1996. His research focused on the epidemiology of autoimmune diseases, with particular interest in the role of the Human Leukocyte Antigen (HLA) genes in the predisposition and severity of Rheumatoid Arthritis. Eric was a pioneer in establishing the influence of certain HLA alleles and haplotypes in the progression of the disease in patients suffering from Rheumatoid Arthritis. He has also served as a mentor to several students who have received their PhD degrees under his guidance.

Eric graduated with a PhD in Immunology from the University of Luminy, now part of the Aix-Marseille University, in France. His dissertation was about the characterization of autoantibodies against thyroid peroxidase in patients suffering from autoimmune thyroiditis.